Report Categories
View AllRecent Articles
View All
FUL H B posts narrow Q1 2026 EPS beat yet shares dip 094 percent amid muted investor sentiment
Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation
Norfolk Southern Corporation NSC Amended Union Pacific Merger Application Faces Regulatory Pushback From Rival CN Rail
LSPD Lightspeed notches small Q1 2026 earnings beat shares climb over two percent on warm investor reception